Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

Hypertension

Volumn 42, Issue 3, 2003, Pages 310-315

  Widlansky, Michael E ^c   Price, Daniel T ^c   Gokce, Noyan ^c   Eberhardt, Robert T ^c   Duffy, Stephen J ^c   Holbrook, Monika ^c   Maxwell, Carolyn ^c   Palmisano, Joseph ^c   Keaney Jr , John F ^c   Morrow, Jason D ^a   Vita, Joseph A ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c NONE

Author keywords

Cyclooxygenase; Endothelium; Hypertension, essential; Prostacyclin

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLYCERYL TRINITRATE; ISOPROSTANE; NITRIC OXIDE; PLACEBO; PROSTANOID; REACTIVE OXYGEN METABOLITE; THROMBOXANE; VASOCONSTRICTOR AGENT;

ADULT; ARTERY DIAMETER; ARTICLE; BIOAVAILABILITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HYPEREMIA; HYPERTENSION; INFLAMMATION; LONG TERM CARE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; ULTRASOUND; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; BRACHIAL ARTERY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NITROGLYCERIN; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; SULFONAMIDES; TIME FACTORS; VASODILATION;

EID: 10744233674     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000084603.93510.28     Document Type: Article

References (40)

1. Gokce N, Vita JA. Clinical manifestations of endothelial dysfunction. In: Loscalzo J, Schafer AI, eds. Thrombosis and Hemorrhage. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:685-706.
2. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
3. Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, Selwyn AP, Alexander RW, Ganz P. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res. 1992; 71:776-781.
4. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
5. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.
6. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension. 1986;8:344-348.
7. Yang D, Feletou M, Levens N, Zhang JN, Vanhoutte PM. A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension. 2003;41:143-148.
8. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effects on endothelial vasomotor function in hypertension. Hypertension. 2000;35:936-941.
9. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis. 1995;38:129-154.
10. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restorers nitric oxide activity in essential hypertension. Hypertension. 1997;29:274-279.
11. Campia U, Choucair WK, Bryant MB, Quyyumi AA, Cardillo C, Panza JA. Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans. Am J Cardiol. 2002;89:286-290.
12. Duffy SJ, Meredith IT. Prostanoids do not affect endothelium-dependent vasodilation in healthy humans. Am J Cardiol. 2002;90:686.
13. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229.
14. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
15. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
16. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
17. Camacho M, Lopez-Belmonte J, Vila L. Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circ Res. 1998;83: 353-365.
18. Goodwin DC, Landino LM, Marnett LJ. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J. 1999;13:1121-1136.
19. Zou MH, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett. 1996;382:101-104.
20. Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Leeuwenburgh C, Heinecke JW, Vita JA. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1999;99:3234-3240.
21. Duffy SJ, Keaney JF Jr, Holbrook M, Gokce N, Swerdloff PL, Frei B, Vita JA. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 2001; 104:151-156.
22. 2a) by a stable isotope dilution mass spectrometric assay. Clin Clin Acta. 2001;314:93-99.
23. 2 by gas chromatography-mass spectrometry. J Chromatogr. 1993;612:179-185.
24. 1a by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl. 1994; 653:117-122.
25. Gokce N, Holbrook M, Duffy SJ. Demissie S, Cupples LA, Biegelsen E, Keaney JF Jr, Loscalzo J, Vita JA. Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension. 2001;38:1349-1354.
26. Vita JA. Nitric oxide-dependent vasodilation in human subjects. Methods Enzymol. 2002;359:186-200.
27. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277.
28. Keaney JF Jr, Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434-439.
29. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
30. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998; 97:716-720.
31. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation. 2001;104:2879-2882.
32. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002;106:640-642.
33. Gokce N, Keaney JF Jr, Menzoian JO, Watkins M, Hunter L, Duffy SJ, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation. 2002;105: 1567-1572.
34. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of non-invasively-determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769-1775.
35. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, Lopez R, Gonzalez C. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation. 2002;106:191-195.
36. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106:167-169.
37. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
38. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
39. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
40. Gerhard M, Walsh MW, Tawakol A, Haley EA, Creager SJ. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation. 1998;98:1158-1163.